This compound was taken into a Phase Ib clinical trial in FRDA patients, where drug treatment lead to increases in FXN mRNA and histone acetylation at the FXN gene in peripheral blood mononuclear cells. This evidence concerns the gene FXN and Friedreich ataxia.